No Prescription |
 |
 | ||
|
Cymbalta Generic Duloxetine |
|
| ||
No Prescription » Prescription Drugs 5 » Cymbalta Generic Duloxetine Duloxetine is used to treat major depression and anxiety. In addition duloxetine is used to relieve nerve pain (peripheral neuropathy) in people with diabetes. It is also used to treat pain caused by a condition called fibromyalgia that affects the muscles tendons ligaments and supporting tissues.This medication is a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by helping to restore the balance of certain natural substances in the brain (neurotransmitters). Duloxetine may improve your mood sleep appetite and energy level and decrease nervousness. It can also decrease pain caused by nerve damage. Buy Cymbalta Generic Duloxetine and other Prescription Drugs 5 products online at Medstore. Buy Online at Medstore - Click Here!
About Cymbalta Generic Duloxetine: Product Type: Prescription Drugs 5 Cymbalta ( Generic Duloxetine ) Cymbalta (Generic Duloxetine) Generic Duloxetine 30mg 28 Capsules 56 Capsules 60mg Generic Duloxetine Cymbalta
View more Prescription Drugs 5 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
